19:15 , Sep 14, 2018 |  BC Week In Review  |  Company News

Oncolytics to conduct pilot study of oncolytic virus with SOLTI

Oncolytics Biotech Inc. (TSX:ONC; NASDAQ:ONCY) partnered with the non-profit group SOLTI (Barcelona, Spain) to conduct a pilot study of the biotech's Reolysin pelareorep in the neoadjuvant setting for breast cancer. SOLTI will facilitate the trial,...
19:34 , Sep 10, 2018 |  BC Innovations  |  Distillery Therapeutics

Cancer

INDICATION: Cancer; colorectal cancer; melanoma Patient sample and mouse studies suggest inhibiting NFKB2 in combination with radiotherapy could help treat cancer. In glioblastoma patients treated with radiotherapy, high postmortem levels of NFKB2 mRNA in brain tissue...
18:42 , Aug 31, 2018 |  BC Week In Review  |  Clinical News

Opdivo gets accelerated approval in SCLC population

FDA granted accelerated approval to Opdivo nivolumab from Bristol-Myers Squibb Co. (NYSE:BMY) to treat small cell lung cancer in a third-line setting. BMS said the approval is the first for an immuno-oncology therapy in the...
18:20 , Aug 31, 2018 |  BC Week In Review  |  Company News

Harbour gets ex-China rights to Kelun's anti-PD-L1 mAb

Sichuan Kelun-Biotech Biopharmaceutical Co. Ltd. granted Harbour BioMed (Shanghai, China) exclusive rights to anti-PD-L1 antibody A167 outside of the Greater China region. Kelun-Biotech is the small molecules and biologics-focused subsidiary of Sichuan Kelun Pharmaceutical Co....
21:12 , Aug 20, 2018 |  BC Extra  |  Company News

Harbour gets ex-China rights to Kelun's anti-PD-L1 mAb

Sichuan Kelun-Biotech Biopharmaceutical Co. Ltd. granted Harbour BioMed (Shanghai, China) exclusive rights to anti-PD-L1 antibody A167 outside of the Greater China region. Kelun-Biotech is the small molecules and biologics-focused subsidiary of Sichuan Kelun Pharmaceutical Co....
15:01 , Aug 17, 2018 |  BC Extra  |  Company News

Opdivo gets accelerated approval in SCLC population

FDA granted accelerated approval to Opdivo nivolumab from Bristol-Myers Squibb Co. (NYSE:BMY) to treat small cell lung cancer in a third-line setting. BMS said the approval is the first for an immuno-oncology therapy in the...
22:10 , Aug 7, 2018 |  BC Extra  |  Preclinical News

Blood-based assay could predict Tecentriq's benefit in NSCLC

A blood-based tumor mutation burden (bTMB) assay could predict anti-PD-L1 mAb Tecentriq atezolizumab's clinical benefit in non-small cell lung cancer patients. The Genentech Inc. unit of Roche (SIX:ROG; OTCQX:RHHBY), Foundation Medicine Inc. (NASDAQ:FMI) and academic...
17:06 , Aug 3, 2018 |  BC Week In Review  |  Clinical News

CHMP positive on patisiran, Symkevi, Humira and Neulasta biosimilars

EMA's CHMP recommended a number of approvals July 26, including Onpattro patisiran from Alnylam Pharmaceuticals Inc. (NASDAQ:ALNY), Symkevi tezacaftor/ivacaftor from Vertex Pharmaceuticals Inc. (NASDAQ:VRTX), a handful of cancer therapies and three biosimilars. The committee recommended approval...
22:08 , Jul 27, 2018 |  BC Extra  |  Company News

CHMP positive on patisiran, Symkevi, Humira and Neulasta biosimilars

EMA's CHMP recommended a number of approvals Friday, including Onpattro patisiran from Alnylam Pharmaceuticals Inc. (NASDAQ:ALNY), Symkevi tezacaftor/ivacaftor from Vertex Pharmaceuticals Inc. (NASDAQ:VRTX), a handful of cancer therapies and three biosimilars. The committee recommended approval of...
22:04 , Jul 19, 2018 |  BC Innovations  |  Tools & Techniques

Immunotherapy Matchmaking

MD Anderson Cancer Center is using its access to patient samples to inject more rationality into decisions about which therapies should be paired with checkpoint inhibitors, and how to optimize the combos. The goal is...